ライフサイエンスコーパス: tachyarrhythmia

1 ed cardiac arrest or spontaneous ventricular tachyarrhythmia).

2 tion to treat potentially lethal ventricular tachyarrhythmia.

3 ulnerability to life-threatening ventricular tachyarrhythmia.

4 iate ICD discharge for sustained ventricular tachyarrhythmia.

5 isodes of spontaneous, sustained ventricular tachyarrhythmia.

6 isodes of spontaneous, sustained ventricular tachyarrhythmia.

7 idered to be from sudden cardiac arrest from tachyarrhythmia.

8 ventricular systolic dysfunction, or atrial tachyarrhythmia.

9 lation and a higher risk of supraventricular tachyarrhythmia.

10 s of atrial tachycardia and supraventricular tachyarrhythmia.

11 ejection fraction and inducible ventricular tachyarrhythmia.

12 ar before their index episode of ventricular tachyarrhythmia.

13 italization for heart failure or ventricular tachyarrhythmia.

14 2) and are associated with fatal ventricular tachyarrhythmia.

15 was an ICD shock for adjudicated ventricular tachyarrhythmia.

16 ectrical activation that promote ventricular tachyarrhythmias.

17 IAT or by the development of in-trial atrial tachyarrhythmias.

18 tion but continuing proneness to ventricular tachyarrhythmias.

19 ue for managing children with JET and atrial tachyarrhythmias.

20 rred in 7 animals, simulating a rapid atrial tachyarrhythmias.

21 t-CRT-D LVEF and ICD therapy for ventricular tachyarrhythmias.

22 oanatomic scar substrate of life-threatening tachyarrhythmias.

23 nary artery disease and unstable ventricular tachyarrhythmias.

24 n death previously attributed to ventricular tachyarrhythmias.

25 s were recurrence of AF and organized atrial tachyarrhythmias.

26 tween patients with and those without atrial tachyarrhythmias.

27 omyopathy, as well as atrial and ventricular tachyarrhythmias.

28 n and a reduction in the risk of ventricular tachyarrhythmias.

29 s an invariable trigger of paroxysmal atrial tachyarrhythmias.

30 with increased susceptibility to ventricular tachyarrhythmias.

31 iods for shock delivery to treat ventricular tachyarrhythmias.

32 ch may promote susceptibility to ventricular tachyarrhythmias.

33 ity to spontaneous and inducible ventricular tachyarrhythmias.

34 entry and may have important implications in tachyarrhythmias.

35 t disease are at higher risk for ventricular tachyarrhythmias.

36 QT prolongation, and spontaneous ventricular tachyarrhythmias.

37 , particularly in the setting of monomorphic tachyarrhythmias.

38 syncope and sudden death due to ventricular tachyarrhythmias.

39 may occur during catheter ablation of atrial tachyarrhythmias.

40 n the initiation and perpetuation of various tachyarrhythmias.

41 onally leading to unstable, self-terminating tachyarrhythmias.

42 iarrhythmic device therapies for ventricular tachyarrhythmias.

43 ce were inducible into sustained ventricular tachyarrhythmias.

44 80% of O-CKO mice were inducible into lethal tachyarrhythmias.

45 d risk of sudden death caused by ventricular tachyarrhythmias.

46 ty and mortality rates from recurrent atrial tachyarrhythmias.

47 had a history of documented sustained atrial tachyarrhythmias.

48 alternans and thereby preventing ventricular tachyarrhythmias.

49 notype of ischemiainduced lethal ventricular tachyarrhythmias.

50 t of ventricular as well as supraventricular tachyarrhythmias.

51 lan radiofrequency ablation for treatment of tachyarrhythmias.

52 standing of the mechanisms and etiologies of tachyarrhythmias.

53 transgenic hearts from malignant ventricular tachyarrhythmias.

54 s to reduce the burden of spontaneous atrial tachyarrhythmias.

55 ents, including life-threatening ventricular tachyarrhythmias.

56 increases in ventricular or supraventricular tachyarrhythmias.

57 d susceptibility to life-threatening cardiac tachyarrhythmias.

58 ality and appropriate shocks for ventricular tachyarrhythmias.

59 aphic risk factors in predicting ventricular tachyarrhythmias.

60 to epicardial fat pads for preventing atrial tachyarrhythmias.

61 opriate ICD therapy or sustained ventricular tachyarrhythmias.

62 jor predisposing factor for life-threatening tachyarrhythmias.

63 ICD shock defined as a shock for ventricular tachyarrhythmias.

64 with a decreased incidence of postoperative tachyarrhythmias.

65 04) and had a comparable incidence of atrial tachyarrhythmias.

66 cardiomyopathy at risk of fatal ventricular tachyarrhythmias.

67 oint (n=22 patients; 19 atrial/2 ventricular tachyarrhythmia, 1 death) included RV LGE presence and e

68 easons included the development of an atrial tachyarrhythmia (18%), loss of left ventricular capture

69 mia incidence between groups became similar: tachyarrhythmias (29% versus 31%; P=0.66), tachyarrhythm

70 edetomidine demonstrated significantly fewer tachyarrhythmias (29% versus 38%; P<0.001), tachyarrhyth

71 an in the placebo group had supraventricular tachyarrhythmia (3.1% vs. 0.4%; absolute difference, 2.7

72 nificantly higher in patients with inducible tachyarrhythmia (58% of deaths in inducible patients ver

73 art rates were more likely to develop atrial tachyarrhythmias, a dual-chamber rate-modulated pacing m

74 risk of atrial fibrillation or other atrial tachyarrhythmias (AF/AT), or if postimplantation AF/AT m

75 rhythms and bradycardia-related ventricular tachyarrhythmias after AVB in mice.

76 ly meaningful difference in the incidence of tachyarrhythmias after congenital heart surgery, it may

77 in patients presenting with supraventricular tachyarrhythmias after surgical correction of congenital

78 herapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy

79 in the risk of life-threatening ventricular tachyarrhythmias among patients with NICM.

80 uce the risk of life-threatening ventricular tachyarrhythmias among patients with nonischemic cardiom

81 er, atrial tachycardia, and supraventricular tachyarrhythmias) among patients enrolled in MADIT-CRT (

82 During tachyarrhythmias, anatomically complex and simplified mo

83 itial treatment of AF, coexistence of atrial tachyarrhythmia and (2) progression of paroxysmal to (lo

84 atients with inducible sustained ventricular tachyarrhythmia and 35% of 1394 patients without inducib

85 dysplasia/cardiomyopathy is associated with tachyarrhythmia and an increased risk of sudden death.

86 2 of 269 patients who had episodes of atrial tachyarrhythmia and had >/=30 days of follow-up with atr

87 se-limiting toxicities were supraventricular tachyarrhythmia and myelosuppression.

88 sodes, with correct detection of ventricular tachyarrhythmia and subsequent shock therapy.

89 outcomes measured were recurrence of atrial tachyarrhythmia and the incidence of adverse events.

90 98 patients, representing 32% of ventricular tachyarrhythmias and 76% of those that would be detected

91 ressor in selected patients with low risk of tachyarrhythmias and absolute or relative bradycardia.

92 In-utero management of tachyarrhythmias and conduction system disease has impro

93 educing the risk of sympathetically mediated tachyarrhythmias and excessive bradycardiac counter-regu

94 tion wavefronts during episodes of simulated tachyarrhythmias and fibrillatory arrhythmias, defined a

95 lecular and mechanistic insights into atrial tachyarrhythmias and identifies Kir3.x as a promising at

96 w the likely mechanism by which they lead to tachyarrhythmias and indicate a distinct role of I(KS) k

97 racking echocardiography predict ventricular tachyarrhythmias and provide incremental prognostic info

98 s included symptomatic recurrences of atrial tachyarrhythmias and quality of life measures assessed b

99 athetic stimulation precipitates ventricular tachyarrhythmias and sudden cardiac death except in Brug

100 art failure have been plagued by ventricular tachyarrhythmias and sudden cardiac death.

101 redisposes to the development of ventricular tachyarrhythmias and sudden death.

102 In this review, common tachyarrhythmias and their current treatments in childre

103 sudden death and, in some cases, ventricular tachyarrhythmias and waxing and waning cardiomyopathy.

104 riefly discuss efforts to address aspects of tachyarrhythmia, and review advances in creating a biolo

105 ure, myocardial infarction, supraventricular tachyarrhythmia, and ventricular tachycardia or fibrilla

106 currence of atrial fibrillation, ventricular tachyarrhythmias, and stroke and length of stay after ca

107 ere arrhythmic among patients with inducible tachyarrhythmia appeared more distinct among patients wi

108 Early recurrences (ERs) of atrial tachyarrhythmia are common after catheter ablation of at

109 Ventricular tachyarrhythmias are characteristic of giant cell myocar

110 t of human heart), and malignant ventricular tachyarrhythmias are infrequent during acute murine myoc

111 Tachyarrhythmias are more common in the Brugada syndrome

112 n for EAM, and inducibility of any sustained tachyarrhythmia at the end of EAM procedure were identif

113 resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 years.

114 strates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk patients who are

115 myocardial biopsy and history of ventricular tachyarrhythmias at presentation (P<0.05 for all).

116 ac resynchronization therapy (CRT) on atrial tachyarrhythmia (AT) susceptibility in patients with lef

117 ndary endpoints included freedom from atrial tachyarrhythmias (AT) at 6 and 12 months, periprocedural

118 a subsequent reduction in the risk of atrial tachyarrhythmias (AT).

119 However, atrial tachyarrhythmias (ATA) are a common early complication a

120 of whom also demonstrated persistent atrial tachyarrhythmias (ATAs).

121 ical end point comprised new-onset sustained tachyarrhythmia (atrial/ventricular) or decompensated he

122 ng an association between subclinical atrial tachyarrhythmias (ATs) detected by cardiac implantable e

123 electrophysiologic studies for induction of tachyarrhythmias based on these trials.

124 ng upstream therapies to abort a ventricular tachyarrhythmia before its onset.

125 tricular ejection fraction, a history of any tachyarrhythmia before the index event and the absence o

126 ular tachyarrhythmias have documented atrial tachyarrhythmias before implantation.

127 was observed in 12-month freedom from atrial tachyarrhythmias between an index ablative approach of s

128 thmias had a significant reduction in atrial tachyarrhythmia burden with use of atrial pacing and sho

129 polarizations (EADs) are a known trigger for tachyarrhythmias, but the conditions that cause surround

130 patients to an increased risk of ventricular tachyarrhythmias, but the incidence of cardiac or sudden

131 The rate of sustained ventricular tachyarrhythmias by 3 months was 3% among patients with

132 termination of life-threatening ventricular tachyarrhythmias by an ICD.

133 These tachyarrhythmias can also begin during cardiopulmonary r

134 Atrial and ventricular tachyarrhythmias can be perpetuated by up-regulation of

135 fectiveness and safety of terminating atrial tachyarrhythmias clinically.

136 a total of 14 patients (11%) had ventricular tachyarrhythmias, compared with 5 (3.8%) in the precedin

137 ays post-9/11, 16 patients (8%) demonstrated tachyarrhythmias, compared with only seven (3.5%) in the

138 d enhances the risk of malignant ventricular tachyarrhythmias complicating AVB.

139 ic mutation in a familial syndrome of atrial tachyarrhythmia, conduction system disease (CSD), and DC

140 ts from the Creighton University ventricular tachyarrhythmia database.

141 outcome event, 11 had had subclinical atrial tachyarrhythmias detected by 3 months, and none had had

142 By 3 months, subclinical atrial tachyarrhythmias detected by implanted devices had occur

143 pids can induce lethal malignant ventricular tachyarrhythmias during acute cardiac ischemia.

144 0/17 (59%) experienced sustained ventricular tachyarrhythmias during follow-up and 3 received intraca

145 mber of spontaneous nonsustained ventricular tachyarrhythmias during stage 2 and the occurrence of is

146 2 and the occurrence of ischemic ventricular tachyarrhythmias during stage 3 also were significantly

147 ith and those without device-detected atrial tachyarrhythmias during the first year.

148 ts for 3 months to detect subclinical atrial tachyarrhythmias (episodes of atrial rate >190 beats per

149 solation (PVI) as early recurrence of atrial tachyarrhythmia (ERAT) may be due to transient proarrhyt

150 was 83.0% for the first clinical ventricular tachyarrhythmia event; there were no differences in shoc

151 n result from coronary artery abnormalities, tachyarrhythmias, exposure to infection or toxins, or se

152 Premature stimulation induced ventricular tachyarrhythmia/fibrillation >60 seconds in 6 of 8 shams

153 incidence of inducible sustained ventricular tachyarrhythmia/fibrillation in canine infarcts.

154 reated by the WCD in response to ventricular tachyarrhythmia/fibrillation.

155 strong predictor of spontaneous ventricular tachyarrhythmia following ST-segment-elevation myocardia

156 n resulted in better 2-year organized atrial tachyarrhythmia-free survival (71% [62%-79%] versus 60%

157 Organized atrial tachyarrhythmia-free survival was similar after SRI and

158 ctional ectopic tachycardia [JET] and atrial tachyarrhythmias) frequently complicate recovery from op

159 Tachyarrhythmia functions were disabled.

160 Magnet response and tachyarrhythmia functions were disabled.

161 Tachyarrhythmia functions were disabled.

162 Patients with atrial tachyarrhythmia >/=30 s within the 3-month blanking peri

163 t and arrhythmic death caused by ventricular tachyarrhythmias >/=240 per minute was observed in 7 and

164 rsion of spontaneously occurring ventricular tachyarrhythmias >200 bpm was identical (97.3%), despite

165 Ventricular tachyarrhythmias had a low positive and relatively high

166 ts with a standard ICD indication and atrial tachyarrhythmias had a significant reduction in atrial t

167 had the Fontan procedure, those with atrial tachyarrhythmias had longer P-wave duration (159+/-28 ve

168 Patients with atrial tachyarrhythmias had longer paced (153+/-29 versus 145+/

169 Using more intervals to detect ventricular tachyarrhythmias has been associated with reducing unnec

170 Radiofrequency (RF) ablation treatment for tachyarrhythmias has been available only for the past 15

171 ter-defibrillator (ICD) to treat ventricular tachyarrhythmias have documented atrial tachyarrhythmias

172 reases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were not spe

173 ffect of both history of intermittent atrial tachyarrhythmias (IAT) and in-trial IAT on the risk of h

174 te between modes of death, whereas inducible tachyarrhythmia identifies patients for whom death, if i

175 Both low ejection fraction and inducible tachyarrhythmias identify patients with coronary disease

176 with a higher incidence of sustained atrial tachyarrhythmia, implying that sinus node dysfunction is

177 yocarditis presented as nonfatal ventricular tachyarrhythmia in 10 patients and as a fatal cardiac ar

178 There was recurrence of atrial tachyarrhythmia in 222 of 785 (28%) patients who underwe

179 Torsade de pointes ventricular tachyarrhythmia in the long QT syndrome is a prime examp

180 aracterized by propensity toward ventricular tachyarrhythmia in the setting of well-preserved morphol

181 des a noninvasive means of analyzing complex tachyarrhythmia in utero, with efficacy approaching that

182 in 166 patients (19%), sustained ventricular tachyarrhythmias in 17 (2%), and permanent pacemakers we

183 d pre-specified protocol induced ventricular tachyarrhythmias in 40% of patients: arrhythmia inducibi

184 ere was a total of 120 sustained ventricular tachyarrhythmias in 41 patients, of whom 54% received ap

185 ppress sympathetic outflow and reduce atrial tachyarrhythmias in ambulatory dogs.

186 reduces the incidences of paroxysmal atrial tachyarrhythmias in ambulatory dogs.

187 preferred first-line approach to symptomatic tachyarrhythmias in children.

188 y improved outcomes in ablative treatment of tachyarrhythmias in children.

189 n (SCS) reduces the incidence of ventricular tachyarrhythmias in experimental models.

190 nic and molecular levels lead to ventricular tachyarrhythmias in HF are unknown.

191 lead ECGs independently predicts ventricular tachyarrhythmias in ICD-eligible cardiomyopathy patients

192 lar rate during postoperative JET and atrial tachyarrhythmias in our young canine open heart surgery

193 as associated with the development of atrial tachyarrhythmias in pacemaker patients.

194 assist device (LVAD) therapy on ventricular tachyarrhythmias in patients with advanced congestive he

195 associated with greater risk of ventricular tachyarrhythmias in patients with cardiovascular disease

196 the treatment strategy of choice for atrial tachyarrhythmias in patients with congenital heart disea

197 trial pacing for treating spontaneous atrial tachyarrhythmias in patients with implantable cardiovert

198 y little apparent role in the maintenance of tachyarrhythmias in the rabbit ventricles and, contrary

199 In contrast, tachyarrhythmias in wild-type hearts (WT) were short-liv

200 LGE-SI is a better predictor of ventricular tachyarrhythmias (including nonsustained ventricular tac

201 ihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter E

202 The incidence of ventricular tachyarrhythmia, including ventricular fibrillation, and

203 f atrial electrophysiology and induce atrial tachyarrhythmias, including atrial tachycardia and atria

204 The frequency of tachyarrhythmias increased significantly for the 30 days

205 orts of R-on-T extrasystoles and ventricular tachyarrhythmia induction as a result of biventricular p

206 ective shock delivery to convert ventricular tachyarrhythmia into sinus rhythm.

207 Atrial tachyarrhythmia is a common cause of morbidity and morta

208 rome associated with polymorphic ventricular tachyarrhythmia is emphasized.

209 In 8 of 9 patients with >1 event, atrial tachyarrhythmia, itself a known risk factor for mortalit

210 Patients with atrial tachyarrhythmias late after Fontan operation have longer

211 Ventricular tachyarrhythmias long enough to cause implantable cardio

212 In patients with CHD, atrial tachyarrhythmias may result from IART or IDAF.

213 ; 95% confidence interval, 0.60 to 0.95) and tachyarrhythmia mortality (adjusted hazard ratio, 0.40;

214 The cardiac and tachyarrhythmia mortality reductions were evident in sub

215 The reduction in tachyarrhythmia mortality with ICD therapy was similar i

216 elicited infrequent monomorphic ventricular tachyarrhythmias (MVT), and dominant frequencies (DFs) d

217 -defibrillator interventions for ventricular tachyarrhythmias (n=31), resuscitated out-of-hospital ca

218 monly with ICD interventions for ventricular tachyarrhythmias (n=33) or heart transplantation for adv

219 nfarction and 1 hypotensive supraventricular tachyarrhythmia), neither of which were fatal or life th

220 Ventricular tachyarrhythmia occurred in 35% of the patients in the l

221 of 1100 episodes of spontaneous ventricular tachyarrhythmias occurred during a mean of 6.9+/-3.6 mon

222 The tachyarrhythmias occurred primarily within 8 days after

223 a, congestive heart failure, and ventricular tachyarrhythmias occurring during the index hospitalizat

224 The time to the first documented atrial tachyarrhythmia of more than 30 seconds (symptomatic or

225 Programming of ICD therapies for tachyarrhythmias of 200 beats per minute or higher or wi

226 We studied prevalence and frequency of tachyarrhythmias on 24-h ambulatory Holter electrocardio

227 Ventricular tachyarrhythmias on Holter electrocardiograms (ECG) have

228 reventing sudden death caused by ventricular tachyarrhythmia or fibrillation.

229 Significant clinical alerts (sustained tachyarrhythmias or an elevated fluid index value) were

230 indications, such as for known or suspected tachyarrhythmias or bradyarrhythmias.

231 w tract) per 24 h; and symptoms, ventricular tachyarrhythmias, or attenuated blood pressure response

232 nt was freedom from recurrence of any atrial tachyarrhythmia, outside a 90-day blanking period, at 12

233 es in ablation and improved understanding of tachyarrhythmias over the past 15 years have greatly imp

234 tion is associated with an increased risk of tachyarrhythmia, palpitations, syncope, and sudden death

235 lity on the ECG and a diagnosis of an atrial tachyarrhythmia predict sudden death.

236 aneous and inducible polymorphic ventricular tachyarrhythmias (PVTs).

237 : tachyarrhythmias (29% versus 31%; P=0.66), tachyarrhythmias receiving intervention (14% versus 17%;

238 tachyarrhythmias (29% versus 38%; P<0.001), tachyarrhythmias receiving intervention (14% versus 23%;

239 Atrial tachyarrhythmias recurred in 28 PVI-only group patients

240 tion group patients, for 1-year freedom from tachyarrhythmia recurrence after a single ablation proce

241 l PVI in achieving freedom from total atrial tachyarrhythmia recurrence at long-term follow-up.

242 or persistent atrial fibrillation and atrial tachyarrhythmia recurrences despite previous successful

243 MIL ablation may reduce organized atrial tachyarrhythmia recurrences.

244 to 8.78) and a clinical diagnosis of atrial tachyarrhythmia (relative risk, 5.18; 95% CI, 2.28 to 11

245 igher risks for life-threatening ventricular tachyarrhythmias remain poorly understood.

246 Subclinical atrial tachyarrhythmias remained predictive of the primary outc

247 rillation is the most frequently encountered tachyarrhythmia requiring therapy.

248 ut the rates of exercise intolerance, atrial tachyarrhythmias, right ventricular dysfunction, and pul

249 The occurrence of ventricular tachyarrhythmias seems to follow circadian, daily, and s

250 ed as predictors of death due to ventricular tachyarrhythmias/sudden death in patients with nonischem

251 ery bypass graft provided substantial atrial tachyarrhythmia suppression both early as well as during

252 Children with incessant tachyarrhythmias (supraventricular arrhythmias [n=26], j

253 enefits, CRT may also ameliorate ventricular tachyarrhythmia susceptibility in HF patients.

254 zation therapy's (CRT) impact on ventricular tachyarrhythmia susceptibility in patients who, due to w

255 anner (relative to date) for all ventricular tachyarrhythmias (tachycardia or fibrillation) triggerin

256 Nonpost-operative JET is a rare tachyarrhythmia that is associated with a high rate of m

257 s can automatically detect and record atrial tachyarrhythmias that may be asymptomatic.

258 e substrate for the development of reentrant tachyarrhythmias that underlie rapid polymorphic VT/VF.

259 ients to assess the incidence of ventricular tachyarrhythmias, the occurrence of shocks, and possible

260 ejection fraction and inducible ventricular tachyarrhythmias to mode of death in all 1791 patients e

261 success rates and have made more complicated tachyarrhythmias treatable with ablation.

262 re for noncardiac surgery recommend that the tachyarrhythmia treatment algorithms of the ICD should b

263 The occurrence of ventricular tachyarrhythmias triggering ICD therapy in the 30 days b

264 and forty-four patients with CHD and atrial tachyarrhythmias undergoing radiofrequency catheter abla

265 CPAP nonusers." The recurrence of any atrial tachyarrhythmia, use of antiarrhythmic drugs, and need f

266 hip between RWT and the risk for ventricular tachyarrhythmia (VA) in patients enrolled in the MADIT-C

267 Programming of ventricular tachyarrhythmia (ventricular tachycardia [VT] or ventric

268 ionship between QRSd and risk of ventricular tachyarrhythmias (ventricular tachycardia/ventricular fi

269 conduction delay, and malignant ventricular tachyarrhythmias (ventricular tachycardia/ventricular fi

270 A total of 34 ventricular tachyarrhythmia/ventricular fibrillation episodes (20 in

271 Spontaneous ventricular tachyarrhythmia (VT)/ventricular fibrillation (VF) event

272 eart disease (SHD) and recurrent ventricular tachyarrhythmias (VT).

273 nd the spontaneous initiation of ventricular tachyarrhythmias (VTA) in humans are unknown.

274 ization (ER) characteristics and ventricular tachyarrhythmias (VTAs) in patients with acute myocardia

275 of heart failure (HF) or death, ventricular tachyarrhythmias (VTAs), and death.

276 6%-50%, and >50%) on outcomes of ventricular tachyarrhythmias (VTAs), VTA >/=200 bpm, ICD shock, hear

277 (CRT) and the risk of subsequent ventricular tachyarrhythmias (VTAs).

278 n Ca(2+) waves, a major cause of ventricular tachyarrhythmias (VTs) and sudden death.

279 d activities, and stress-induced ventricular tachyarrhythmias (VTs) in a mouse model of cardiac ryano

280 with an enhanced propensity for ventricular tachyarrhythmias (VTs) under conditions of metabolic dem

281 One-year freedom from symptomatic atrial tachyarrhythmia was 77.2% in patients without ER compare

282 collapse rhythm was evaluated, a ventricular tachyarrhythmia was observed in 9.

283 embolism associated with subclinical atrial tachyarrhythmias was 13%.

284 ences of atrial fibrillation or other atrial tachyarrhythmias was evaluated at the end of the follow-

285 First shock efficacy for ventricular tachyarrhythmias was high regardless of baseline DFT tes

286 Subclinical atrial tachyarrhythmias were associated with an increased risk

287 mice, spontaneous and inducible ventricular tachyarrhythmias were common, occurring in 60% and 86%,

288 terventions for life-threatening ventricular tachyarrhythmias were frequent and highly effective in r

289 ons terminating life-threatening ventricular tachyarrhythmias were frequent.

290 Adrenergically triggered tachyarrhythmias were more frequent in RyR2-V2475F(+/-)

291 tion, but appropriate shocks for ventricular tachyarrhythmias were noted only in a minority of patien

292 HCM cohort, ventricular and supraventricular tachyarrhythmias were particularly frequent and demonstr

293 ms (an indicator of potential of ventricular tachyarrhythmia) were reported.

294 siologic mechanism of atrial and ventricular tachyarrhythmias, whether they are sustained, nonsustain

295 s were incorrectly classified as ventricular tachyarrhythmia, which led to inappropriate shock delive

296 Second, the patients with atrial tachyarrhythmias who had the Fontan procedure had larger

297 st 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy, sudden cardi

298 one third of the patients had a ventricular tachyarrhythmia within the last hour of life.

299 n wild-type mice), and malignant ventricular tachyarrhythmias within minutes of ischemia.

300 y reduced sudden death caused by ventricular tachyarrhythmias without affecting heart failure deaths

301 Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation,